Avita Medical Inc (RCEL) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Avita Medical Inc   (NASDAQ: RCEL)

Avita Medical Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Avita Medical Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Avita Medical Inc 's return on equity (ROE) in its third quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -36 -43 -45 -49 -49
Return On Equity (TTM) - - - - -
RCEL's Total Ranking # # # # #
Equity (TTM) in Millions -31 -28 -23 -17 -7
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to RCEL Management Effectiveness >> RCEL's 5 Years Annual ROE >> Compare RCEL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 



  News about Avita Medical Inc Return on Equity ROE

Avita Medicals Third Quarter Navigating Challenges Amidst Market Performance

Avita Medical Inc. a biotech firm specializing in regenerative medicine, has released its financial results for the third quarter, revealing a mixed bag of outcomes that has left investors concerned about its trajectory. While the company s innovative skin treatment products demonstrate potential in a rapidly evolving healthcare landscape, recent stock performance has not been as encouraging.Throughout this month, Avita Medical s shares have underperformed relative to the broader market. Over the past 12 months, the company s stock has gained a modest 7.31%, significantly trailing the impressive 40.39% growth experienced by the market as a whole. This lag raises questions about investor confidence in Avita s growth strategy and its ability to capitalize on emerging opportunities.



RCEL Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Jun 30 2021)
2021
Total Equity in Millions -17 4 49 85 116
Y / Y Equity Change - -90.83 % -42.11 % -26.73 % 59.74 %
Net Income in Millions -49 -62 -35 -27 -27
Y / Y Net Income Change - - - - -
Return On Equity - -1374.64 % -72.12 % -31.47 % -22.98 %

Back to RCEL Management Effectiveness >> RCEL's 5 Years Annual ROE >> Compare RCEL ROE to its Competitors




More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RCEL's' Return on Equity at Yahoo Finance
RCEL's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RCEL's Competitors
Subscribers only: Roe for Avita Medical Inc 's Suppliers
Subscribers only: Return On Equity for RCEL's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Alnylam Pharmaceuticals Inc   159.72 %
Amneal Pharmaceuticals Inc   157.05 %
Alector Inc   112.21 %
Medpace Holdings Inc   99.76 %
3m Company  93.07 %
Exelixis Inc   85.83 %
Amgen Inc   85.59 %
Eli Lilly And Company  83.65 %
Rigel Pharmaceuticals Inc  73.94 %
Idexx Laboratories Inc  71.18 %
Tenet Healthcare Corp  57.13 %
Aurinia Pharmaceuticals Inc   51.92 %
Nurix Therapeutics Inc   49.34 %
Carlisle Companies Incorporated  44.18 %
Bristol myers Squibb Company  43.83 %
Zevra Therapeutics Inc   38.02 %
Dexcom Inc   36.56 %
Rallybio Corporation  36.35 %
Caredx Inc   34.08 %
Chemed Corporation  32.10 %
Illumina Inc   31.45 %

Date modified: 2026-11-08T19:41:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.